Cardiff Oncology Share Price (NASDAQ: CRDF)

$2.09

▲

0.01

(0.48%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Cardiff Oncology Stock chart to analyse performance

Cardiff Oncology stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$2.07
Today's High:$2.13
$2.09
1.2%
Downside
Day's Volatility :3.05%
Upside
1.88%
52 Weeks Low:$2.07
52 Weeks High:$5.64
$2.09
1.2%
Downside
52 Weeks Volatility :63.38%
Upside
62.94%

Cardiff Oncology Stock Returns

Period	Cardiff Oncology Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-37.31%	3.6%	0.0%
6 Months	-44.95%	-7.7%	0.0%
1 Year	-4.11%	-12.6%	0.0%
3 Years	-26.06%	9.5%	-4.7%

Cardiff Oncology Inc Key Stats

Check Cardiff Oncology key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$2.08
Open	$2.115
Today's High	$2.13
Today's Low	$2.065
Market Capitalization	$138.4M
Today's Volume	$863.2K
52 Week High	$5.6395
52 Week Low	$2.065
Revenue TTM	$545.0K
EBITDA	$-53.9M
Earnings Per Share (EPS)	$-0.87
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-91.93%

Stock Returns calculator for Cardiff Oncology Stock including INR - Dollar returns

The Cardiff Oncology stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Cardiff Oncology investment value today

Current value as on today

₹95,760

Returns

₹4,240

(-4.24%)

Returns from Cardiff Oncology Stock

₹9,524 (-9.52%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Cardiff Oncology Stock

43%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Cardiff Oncology Stock from India on INDmoney has increased by 43% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Cardiff Oncology Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
5.78%
Vanguard Group Inc
5.60%
Blair William & Co
3.79%
Pfizer Inc
3.63%
Adage Capital Partners Gp LLC
2.17%
Geode Capital Management, LLC
2.10%

Analyst Recommendation on Cardiff Oncology Stock

Rating

Trend

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Cardiff Oncology(by analysts ranked 0 to 5 stars)

Cardiff Oncology Share Price Target

What analysts predicted

Upside of 381.89%

Target:

$10.07

Current:

$2.09

Cardiff Oncology share price target is $10.07, a slight Upside of 381.89% compared to current price of $2.09 as per analysts' prediction.

Cardiff Oncology Stock Insights

Price Movement
In the last 7 days, CRDF stock has moved down by -9.5%
Increasing Revenue
Revenue is up for the last 2 quarters, 109.0K → 121.0K (in $), with an average increase of 9.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -11.78M → -13.94M (in $), with an average decrease of 8.9% per quarter
CRDF vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 79.0%
CRDF vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 125.5%
Price to Sales
ForCRDF every $1 of sales, investors are willing to pay $233.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Cardiff Oncology Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$245.0K	↓ 35.19%
Net Income	$-16.4M	↓ 0.29%
Net Profit Margin	-6.7K%	↓ 2344.83%

	FY20	Y/Y Change
Revenue	$366.0K	↑ 49.38%
Net Income	$-19.3M	↑ 17.46%
Net Profit Margin	-5.3K%	↑ 1431.74%

	FY21	Y/Y Change
Revenue	$359.0K	↓ 1.91%
Net Income	$-28.3M	↑ 46.74%
Net Profit Margin	-7.9K%	↓ 2612.65%

	FY22	Y/Y Change
Revenue	$386.0K	↑ 7.52%
Net Income	$-38.7M	↑ 36.81%
Net Profit Margin	-10.0K%	↓ 2146.44%

	FY23	Y/Y Change
Revenue	$488.0K	↑ 26.42%
Net Income	$-41.4M	↑ 7.07%
Net Profit Margin	-8.5K%	↑ 1534.93%

	FY24	Y/Y Change
Revenue	$683.0K	↑ 39.96%
Net Income	$-45.4M	↑ 9.63%
Net Profit Margin	-6.7K%	↑ 1840.33%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$205.0K	↑ 31.41%
Net Income	$-10.0M	↑ 7.22%
Net Profit Margin	-4.9K%	↑ 1101.85%

	Q2 FY24	Q/Q Change
Revenue	$163.0K	↓ 20.49%
Net Income	$-11.8M	↑ 17.65%
Net Profit Margin	-7.2K%	↓ 2342.36%

	Q3 FY24	Q/Q Change
Revenue	$165.0K	↑ 1.23%
Net Income	$-11.9M	↑ 0.65%
Net Profit Margin	-7.2K%	↑ 40.92%

	Q4 FY24	Q/Q Change
Revenue	$151.0K	↓ 8.48%
Net Income	$-11.8M	↓ 0.57%
Net Profit Margin	-7.8K%	↓ 621.11%

	Q1 FY25	Q/Q Change
Revenue	$109.0K	↓ 27.81%
Net Income	$-13.4M	↑ 13.97%
Net Profit Margin	-12.3K%	↓ 4518.81%

	Q2 FY25	Q/Q Change
Revenue	$121.0K	↑ 11.01%
Net Income	$-13.9M	↑ 3.83%
Net Profit Margin	-11.5K%	↑ 796.67%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-10.9M	↑ 4885.04%

	FY20	Y/Y Change
Profit	$-10.9M	↓ 0.44%

	FY21	Y/Y Change
Profit	$-141.0K	↓ 98.7%

	FY22	Y/Y Change
Profit	$186.0K	↓ 231.91%

	FY23	Y/Y Change
Profit	$488.0K	↑ 162.37%

	FY24	Y/Y Change
Profit	$683.0K	↑ 39.96%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$103.0K	↑ 94.34%

	Q2 FY24	Q/Q Change
Profit	$58.0K	↓ 43.69%

	Q3 FY24	Q/Q Change
Profit	$165.0K	↑ 184.48%

	Q4 FY24	Q/Q Change
Profit	$55.0K	↓ 66.67%

	Q1 FY25	Q/Q Change
Profit	$109.0K	↑ 98.18%

	Q2 FY25	Q/Q Change
Profit	$121.0K	↑ 11.01%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-13.3M	↑ 0.52%
Investing Cash Flow	$-67.6K	↓ 394.01%
Financing Cash Flow	$12.1M	↓ 26.37%

	FY20	Y/Y Change
Operating Cash Flow	$-16.3M	↑ 22.96%
Investing Cash Flow	$-211.9K	↑ 213.33%
Financing Cash Flow	$137.3M	↑ 1036.88%

	FY21	Y/Y Change
Operating Cash Flow	$-23.0M	↑ 41.22%
Investing Cash Flow	$-131.4M	↑ 61938.89%
Financing Cash Flow	$35.5M	↓ 74.18%

	FY22	Y/Y Change
Operating Cash Flow	$-33.8M	↑ 46.79%
Investing Cash Flow	$38.1M	↓ 129.02%
Financing Cash Flow	$75.0K	↓ 99.79%

	FY23	Y/Y Change
Operating Cash Flow	$-30.9M	↓ 8.67%
Investing Cash Flow	$36.2M	↓ 5.12%
Financing Cash Flow	$0.0	↓ 100.0%

	FY24	Y/Y Change
Operating Cash Flow	$-37.7M	↑ 22.04%
Investing Cash Flow	$13.7M	↓ 62.07%
Financing Cash Flow	$53.8M	-

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-7.7M	↑ 8.42%
Investing Cash Flow	$4.6M	↓ 65.81%
Financing Cash Flow	$107.0K	↑ 791.67%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-9.2M	↑ 19.25%
Investing Cash Flow	$14.0M	↑ 202.31%
Financing Cash Flow	$2.1M	↑ 1823.36%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-10.5M	↑ 13.28%
Investing Cash Flow	$-9.4M	↓ 167.31%
Financing Cash Flow	$7.4M	↑ 260.88%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-10.3M	↓ 1.81%
Investing Cash Flow	$4.5M	↓ 147.82%
Financing Cash Flow	$44.2M	↑ 494.96%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-12.8M	↑ 24.61%
Investing Cash Flow	$-14.6M	↓ 423.3%
Financing Cash Flow	$3.0K	↓ 99.99%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-8.3M	↓ 34.91%
Investing Cash Flow	$-5.0M	↓ 65.83%
Financing Cash Flow	$0.0	↓ 100.0%

Cardiff Oncology Technicals Summary

Sell

Neutral

Buy

Cardiff Oncology is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Cardiff Oncology Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cardiff Oncology Inc	-11.39%	-44.95%	-4.11%	-26.06%	-72.55%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cardiff Oncology Inc	NA	NA	NA	-0.85	-0.92	-0.48	NA	0.88
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cardiff Oncology Inc	Buy	$138.4M	-72.55%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Organization	Cardiff Oncology
Employees	32
CEO	Dr. Mark Erlander Ph.D.
Industry	Health Services

Key Management of Cardiff Oncology Inc

Name	Title
Dr. Mark Erlander Ph.D.	CEO & Director
Mr. James E. Levine	Chief Financial Officer
Dr. Tod Smeal Ph.D.	Chief Scientific Officer
Ms. Elizabeth Anderson	VP of Finance & Administration
Ms. Brigitte Lindsay	Senior Vice President of Finance
Mr. Charles Monahan R.Ph.	Senior Vice President of Regulatory Affairs
Dr. Roger Sidhu M.D.	Chief Medical Officer

Important FAQs about investing in CRDF Stock from India :

What is Cardiff Oncology share price today?

Cardiff Oncology share price today is $2.09 as on August 30, 2025 at 1:29 am IST at the close of the market. Cardiff Oncology share today touched a day high of $2.13 and a low of $2.07.

What is the 52 week high and 52 week low for Cardiff Oncology share?

Cardiff Oncology share touched a 52 week high of $5.64 and a 52 week low of $2.07. Cardiff Oncology stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $2.09, lower by 62.94% versus the 52 week high.

How to invest in Cardiff Oncology Stock (CRDF) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cardiff Oncology on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cardiff Oncology Shares that will get you 0.7177 shares as per Cardiff Oncology share price of $2.09 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Cardiff Oncology Stock (CRDF) from India?

Indian investors can start investing in Cardiff Oncology (CRDF) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Cardiff Oncology stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Cardiff Oncology share’s latest price of $2.09 as on August 30, 2025 at 1:29 am IST, you will get 4.7847 shares of Cardiff Oncology. Learn more about fractional shares .

What are the returns that Cardiff Oncology has given to Indian investors in the last 5 years?

Cardiff Oncology stock has given -72.55% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?